ReviewMolecules (Basel, Switzerland)2024
Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine.
Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026Review
- Bridging the Lab-to-Clinic Gap in Intranasal Nanomaterial-Based Chemotherapy for Glioblastoma.Pharmaceutics · 2026Review
- Doxorubicin-Incorporated Nanoparticles Composed of Ce6-Conjugated Hyaluronic Acid-International journal of molecular sciences · 2026Article
- Inhibiting lactylation for efficient treatment of renal fibrosis through targeting nanomedicine of renal lactate accumulation in obstructed kidney.Journal of nanobiotechnology · 2026Article
- Nanoparticle Clearance and New Horizons in Engineered Drug Delivery.Pharmaceutics · 2026Review
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Smart nanosystems for disease-resistant potatoes: a new Frontier in nanobiotechnology.RSC advances · 2026Review
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Experimental and theoretical evaluation of geometry-dependent doxorubicin loading onto cerium oxide nanoparticles via van der Waals interaction modeling.Scientific reports · 2026Article
- Biosynthesis and characterization of zinc oxide nanoparticles using Dennettia tripetala for the antioxidant and drug release potentials.Scientific reports · 2025Article
- Matrix-bound nanovesicles isolated from decellularized tumors as platforms for targeting parent tumor cells and tumor-associated stromal cells.Materials today. Bio · 2025Article
- Therapeutic Potential of Nanoscale Metal-Organic Frameworks in Hepatocellular Carcinoma.Nanomaterials (Basel, Switzerland) · 2025Review
- Investigating adsorption of 5-fluorouracil and 6-mercaptopurine on icosahedral silver nanoparticles through DFT and TDDFT.Scientific reports · 2025Article
- WNT pathway inhibition sensitizes HAT1-high lung cancers to treatment with PD-1 inhibitors.Cancer cell international · 2025Article
- Gold nanoparticles functionalised with vancomycin enhance antibacterial activity and inhibit Streptococcus pneumoniae adherence and invasion in alveolar cells.The Journal of antibiotics · 2025Article
- Bionanomaterials or Nanobiomaterials: Differences in Definitions and Applications.Journal of functional biomaterials · 2025Review
- Inorganic Silica Nanoparticles Increase Lysosomal Biology and Protease Activity.International journal of molecular sciences · 2025Article
- Carbon-based nanotechnology for Parkinson's disease: diagnostic and therapeutic innovations.Nanomedicine (London, England) · 2025Review
- Nanomedicine: The Effective Role of Nanomaterials in Healthcare from Diagnosis to Therapy.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened the treatment outcomes. These factors often lead to treatment failure via different drug resistance mechanisms. More so, the cost of developing newer drugs is huge. This underscores the need for a paradigm shift in the drug delivery approach in order to achieve desired treatment outcomes. There is intensified research in nanomedicine, which has shown promises in improving the therapeutic outcome of drugs at preclinical stages with increased efficacy and reduced toxicity. Regardless of the huge benefits of nanotechnology in drug delivery, challenges such as regulatory approval, scalability, cost implication and potential toxicity must be addressed via streamlining of regulatory hurdles and increased research funding. In conclusion, the idea of nanotechnology in drug delivery holds immense promise for optimizing therapeutic outcomes. This work presents opportunities to revolutionize treatment strategies, providing expert opinions on translating the huge amount of research in nanomedicine into clinical benefits for patients with resistant infections and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.